Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
The goal of this clinical study is to determine the dosing and safety of labetuzumab govitecan (formerly known as IMMU-130; hMN-14-SN38, antibody-drug conjugate) in participants with colorectal cancer.
Metastatic Colorectal Cancer|Colon Cancer|Rectal Cancer
DRUG: Labetuzumab Govitecan (LG)
Percentage of Participants With Adverse Events and Serious Adverse Events (SAEs), From first dose date up to approximately 2 years after the last dose or until disease progression|Percentage of Participants With Laboratory Abnormalities, From first dose date up to approximately 2 years after the last dose or until disease progression
Duration of Response, Duration of response (DOR) is defined as the interval from the first documentation of PR or CR to the earlier of the first documentation of disease progression (PD) or death from any cause., From first documentation of PR or CR to the earlier of the first documentation of PD or death from any cause (Up to approximately 2 years after the last dose or until disease progression)|Progression-free Survival, Progression free survival (PFS) is defined as the interval from the start of study drug treatment to the earlier of the first documentation of disease progression or death from any cause., From first dose date up to 12 weeks post treatment (Up to approximately 2 years after the last dose or until disease progression)|Time to Progression, Time to progression is defined as the interval from the first dose of treatment to the first documentation of disease progression (PD)., From first dose of study treatment up to PD (Up to approximately 2 years after the last dose or until disease progression)|Overall Survival, Overall survival is defined as the time from start of study drug treatment to death from any cause., From first dose date up to approximately 2 years|Time-to-treatment Failure, Time to treatment failure (TTF) is defined as the interval from the start of treatment to the earlier of the first documentation of disease progression or death due to any cause, the permanent cessation of LG therapy due to all reasons except progressive disease, participant died or lost to follow up., From first dose date up to 8 treatment cycles (each cycle = 21 days) (Up to approximately 24 weeks)|Change from Baseline in Carcinoembryonic Antigen (CEA) Serum Levels, From first dose date up to approximately 2 years after the last dose or until disease progression
The goal of this clinical study is to determine the dosing and safety of labetuzumab govitecan (formerly known as IMMU-130; hMN-14-SN38, antibody-drug conjugate) in participants with colorectal cancer.